Topline Bio

Clinical Insight Gathering Across the Nation, Storytelling in a Digital World.

[Topline Bio @ToplineBio]

@DrChoueiri @FIFAWorldCup @FIFAcom @fifacom_es @fifaworldcup_es @espn @FOXSoccer @MLS @M6 @USMNT @SpainIsFootball Perfectly said. Viva España!

[Ernst Lengyel @ErnstLengyel]

Proud to share our new @Nature study: We developed the 1st NNMT inhibitor that reprograms cancer-associated fibroblasts, boosting immune response & stopping tumor growth in ovarian cancer models, especially when paired with immunotherapy. @OvCa_UChicago

https://t.co/G2QtUZWPPN

[Timothée Olivier, MD @Timothee_MD]

Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive!

Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival. However, there was always the question of systematic bias selecting for healthier patients in morning infusions, when frailer patients may not be able to come to receive morning infusions. This could potentially explain retrospective results, that may seem too good to be true…

Now we have a randomized clinical trial coming from Dr Zhang and colleagues showing a hazard ratio for Overall Survival of … 0.45 ! Lung cancer, chemo-immunotherapy first-line

Looking forward to dig further into the data, and these findings for sure have to be replicated (we are working on that 🇨🇭 @SAKK_ch)

But impressive efforts and results, congrats to the authors.👏 @Alfdoc2

[Uromigos @Uromigos]

Check out our 2024 year in review videos for a meeting-by-meeting summary of highlights across GU malignancies at https://t.co/iOzhXWYte4 in collaboration with @ToplineBio

[Kidney Cancer @KidneyCancer]

We are excited to partner with @ToplineBio Topline Bio for a new era of digital education and storytelling to serve both the healthcare professionals treating #kidneycancer and the patients and families impacted.

Read more: https://t.co/jvefMU64WO

[Topline Bio @ToplineBio]

@Uromigos : Further efforts in advanced bladder cancer will focus on how to optimize the amount of therapy for a given patient so as not to overtreat patients and expose them to excess toxicity without additional benefit.

[Topline Bio @ToplineBio]

@Uromigos : Further efforts in advanced bladder cancer will focus on how to optimize the amount of therapy for a given patient so as not to overtreat patients and expose them to excess toxicity without additional benefit.

[Topline Bio @ToplineBio]

Dr. Powles of the @Uromigos sinks his teeth into ctDNA as an emerging, powerful tool to monitor prostate patients on therapy and how it may add to existing prognostic models…

[Topline Bio @ToplineBio]

KIM-1 is a soluble protein with prognostic and predictive potential in resected RCC.  For more from the @Uromigos on the data from IMmotion 010, click the link below…

https://t.co/EDzTXcdNuZ

[Brian Rini, MD @brian_rini]

Thank you for being one of the Tres Uramigas!!

[Topline Bio @ToplineBio]

Follow Topline Bio for more from @brian_rini👍👍 Chemotherapy plus nivolumab has benefit in advanced bladder cancer, especially in the biologically-distinct subset of patients with lymph node only disease, just ask @Uromigos

[Topline Bio @ToplineBio]

Chromophobe RCC is a rare subtype of kidney cancer. Clinical outcomes from a large institution-based cohort are presented supporting IO-based combination therapy.  @brian_rini shares his perspective…

[Topline Bio @ToplineBio]

@Uromigos focus on CDK 4/6 inhibition.  CDK 4/6 did not produce benefit in mCRPC in a large phase 3 trial and the role of CDK inhibition in prostate cancer remains uncertain.

[Topline Bio @ToplineBio]

@Uromigos discuss Enfortumab vedotin (EV), an active agent in advanced bladder cancer and its efficacy/toxicity related to drug exposure. Early recognition and management of toxicity is critical…

[Topline Bio @ToplineBio]

The emergence of more active bladder cancer systemic therapy has led to more patients with initial advanced disease who could be considered for consolidative cystectomy. @Uromigos debate the timing and role of this maneuver…

[Topline Bio @ToplineBio]

@Uromigos discussing the combination of Abiraterone/Cabazitaxel and its modest clinical benefit in taxane-refractory mCRPC… but is it likely to affect clinical practice?

Enjoy the full clip here : https://t.co/DeLWWpswqJ

[Topline Bio @ToplineBio]

@DrChoueiri @KarlSemaan @RashadNawfal @yekeduz_emre @DrYukselUrun @Clara__Steiner @ReneeSaliby @Chrislabaki1 @MarcMachaalani @marc_eid @RazaneHChehade Viva España!!!! La furia Roja 🇪🇸

[Topline Bio @ToplineBio]

@Uromigos discuss recent data regarding biomarkers of response in metastatic clear cell carcinoma. Some advances have been made yet more work is required to impact patient care… #gucancer #kidneycancer #ASCO24

[Topline Bio @ToplineBio]

The exciting advancements of targeted therapies in gynecologic cancer brings hope to patients. 2024 has been an exciting year for the integration of targeted therapies in GYN oncology, bringing hope to patients and providers alike. #cervicalcancer #endometrialcancer